Thrombophlebitis

IBSA Group and Granata Bio announces first patient screened in pivotal PROGRESS clinical trial of Progesterone-IBSA

Retrieved on: 
Wednesday, October 19, 2022
Reproductive health, Disease, Centers for Disease Control and Prevention timeline, Woman, Vaginal bleeding, Blastocyst, Luteal phase, Progesterone, Patient, ART, Malignancy, Multimedia, IBSA, Transfer, Rest, Plasma protein binding, III, Marketing, Health, CEO, PROGRESS, Breast, Ageing, Safety, Clinical trial, Infertility, Liver, Center, Pregnancy, Thrombophlebitis, Apoplexy, Prevention, Pharmaceutical industry, Birth control

BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).

Key Points: 
  • BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).
  • The study is expected to enroll about 680 patients between the ages of 35-42 years old.
  • "The IBSA Group is excited for this key milestone in development of our subcutaneous progesterone in the United States.
  • IBSA Group, headquartered in Lugano, Switzerland, is a leader in reproductive health and has a diversified product portfolio of prescription drugs and biologics.

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Wednesday, July 13, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Thrombophlebitis, Marketing, Hypophosphatemia, Incidence, Hypokalemia, Bladder cancer, G1 Therapeutics, Therapy, Lung, National Medical Products Administration, G1, Trilaciclib, History, Pneumonitis, Headache, NMPA, Hypocalcemia, Aplastic anemia, Patient, Pneumonia, Adult, Food, GLOBE, RESEARCH, Colorectal cancer, U.S. Securities and Exchange Commission, Breast, Risk, Private Securities Litigation Reform Act, Nasdaq, Phlebitis, Forward-looking statement, Fatigue, FDA, PARK, Simcere Pharmaceutical, Research Triangle Park, Cancer, Interstitial lung disease, Pharmaceutical industry, Vaccine

COSELA is now indicated in China to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer.

Key Points: 
  • COSELA is now indicated in China to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer.
  • G1 may also receive double-digit royalties on annual net sales of COSELA in China.
  • It is predicted that, by 2040, the number of new cancer patients requiring chemotherapy in China will reach 4.2 million.
  • COSELA (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force

Retrieved on: 
Thursday, December 16, 2021
Organization, Forward-looking statement, Trilaciclib, Therapy, Research Triangle Park, U.S. Securities and Exchange Commission, Food, Headache, Bladder cancer, Phlebitis, FDA, Company, History, Pneumonia, Adult, Pneumonitis, Interstitial lung disease, Private Securities Litigation Reform Act, Hypocalcemia, Sale, Nasdaq, Event, Incidence, Breast, Hypophosphatemia, Cancer, Adoption, Fatigue, G1 Therapeutics, RESEARCH, Lung, Regulation of tobacco by the U.S. Food and Drug Administration, Thrombophlebitis, Goal, Patient, Boehringer Ingelheim, Risk, GLOBE, Hypokalemia, G1, PARK, Webcast, Pharmaceutical industry, Online shopping, Vaccine

RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34. The expansion will allow G1 to target all accounts to accelerate sales activities and help maximize the adoption of COSELA™ (trilaciclib). G1 and Boehringer Ingelheim have mutually agreed to end the co-promotion agreement for COSELA, effective March 2022.

Key Points: 
  • The expansion will allow G1 to target all accounts to accelerate sales activities and help maximize the adoption of COSELA (trilaciclib).
  • G1 and Boehringer Ingelheim have mutually agreed to end the co-promotion agreement for COSELA, effective March 2022.
  • ET today to discuss the expansion of the COSELA sales force.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy

Retrieved on: 
Thursday, October 7, 2021
Fatigue, Incidence, History, Headache, Failure rate, Therapy, Trilaciclib, Adult, Birth, Bleeding, ILD, Caregiver, MD Anderson Cancer Center, Hypokalemia, Department, Food, RESEARCH, Squamous cell carcinoma, NSCLC, SCLC, GLOBE, Diagnosis, Cancer, Pneumonitis, Lung, Thrombosis, CDK, Lung cancer, MD, Â, Fatal, Regulation of tobacco by the U.S. Food and Drug Administration, Neutropenia, Sepsis, Treatment of lung cancer, ESA, Hypophosphatemia, PARK, Survival rate, Phlebitis, Protein kinase, Pâ, Aplastic anemia, ESAS, Pneumonia, Cancer Medicine, Associate professor, Thrombophlebitis, Hypocalcemia, CIM, Nasdaq, Pharmaceutical industry, Vaccine

COSELA (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

Key Points: 
  • COSELA (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
  • The publication titled, Trilaciclib Prior to Chemotherapy Reduces the Usage of Supportive Care Interventions for Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: Pooled Analysis of Three Randomized Phase 2 Trials, can be accessed here .
  • By reducing the need for associated supportive care, trilaciclib has the potential to reduce both the societal and economic burden of chemotherapy-induced myelosuppression.
  • SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers.

G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services

Retrieved on: 
Friday, October 1, 2021
Food, Therapy, Breast, Insurance, Centers for Medicare & Medicaid Services, Research Triangle Park, Lung, Risk, Interstitial lung disease, Regulation of tobacco by the U.S. Food and Drug Administration, G1 Therapeutics, Fatigue, RESEARCH, Private Securities Litigation Reform Act, Hypophosphatemia, Cancer, Medicare, HCPCS, Medicaid, FDA, U.S. Securities and Exchange Commission, Patient, CMS, Pneumonitis, Hypokalemia, Bladder cancer, PARK, Hypocalcemia, Adult, Hospital, Medicare Advantage, Healthcare Common Procedure Coding System, NTAP, Center, Pneumonia, Injection, Phlebitis, Trilaciclib, Incidence, Medicare (United States), History, Forward-looking statement, Thrombophlebitis, Nasdaq, Government, Headache, Medicare Part D, GLOBE, Pharmaceutical industry, Health insurance, Medical imaging, Vaccine

With the permanent J-code now in effect, all hospital outpatient departments, ambulatory surgery centers and physician offices in the United States will have one consistent Healthcare Common Procedure Coding System (HCPCS) code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans.

Key Points: 
  • With the permanent J-code now in effect, all hospital outpatient departments, ambulatory surgery centers and physician offices in the United States will have one consistent Healthcare Common Procedure Coding System (HCPCS) code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans.
  • https://www.g1therapeutics.com/cosela/pi/
    To report suspected adverse reactions, contact G1 Therapeutics at 1-800-790-G1TX or call FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force

Retrieved on: 
Wednesday, September 15, 2021
Squamous cell carcinoma, Hypocalcemia, Headache, Bladder cancer, Therapy, Food, Incidence, Regulation of tobacco by the U.S. Food and Drug Administration, Board, FDA, BI, Forward-looking statement, G1 Therapeutics, Adoption, Trilaciclib, Patient, Thrombophlebitis, Hypophosphatemia, Director, Private Securities Litigation Reform Act, Nasdaq, U.S. Securities and Exchange Commission, Risk, Research Triangle Park, Medicine, Employment, Hypokalemia, Fatigue, RESEARCH, Adult, Boehringer Ingelheim, Breast, PARK, Pneumonia, Interstitial lung disease, GLOBE, Phlebitis, History, Pneumonitis, Lung, Cancer, Plan, Fine chemical, Medical imaging, Pharmaceutical industry, Vaccine

The expansion will allow G1 to target top tier accounts in order to accelerate sales activities and help maximize the adoption of COSELA (trilaciclib).

Key Points: 
  • The expansion will allow G1 to target top tier accounts in order to accelerate sales activities and help maximize the adoption of COSELA (trilaciclib).
  • G1 entered into a three-year co-promotion agreement with Boehringer Ingelheim to collaborate on the commercialization of COSELA for its first indication in ES-SCLC.
  • On September 9, 2021, the G1 Board of Directors adopted the G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan (the Plan).
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

Retrieved on: 
Wednesday, August 4, 2021
Organic compounds, Chemical compounds, Chemistry, Medical terminology, Healthcare reform in the United States, Diagnosis-related group, G1 Therapeutics, Trilaciclib, Medicare, G1, Garbage-first collector

An NTAP provides additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount.

Key Points: 
  • An NTAP provides additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount.
  • As such, beginning on October 1, 2021, CMS will provide an additional maximum payment of$5,526.30for COSELA when used in the inpatient hospital setting for fiscal year 2022.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19

Retrieved on: 
Tuesday, December 29, 2020
Medical specialties, Clinical medicine, Medicine, Vascular diseases, Heparins, Glycosaminoglycans, Hematology, Franciosi, Thrombophlebitis, Anticoagulant, Phlebitis, Thrombosis

The clinically best-known GAG is heparin, which is an anticoagulant used for the treatment of thrombophlebitis, embolism, and thrombosis.

Key Points: 
  • The clinically best-known GAG is heparin, which is an anticoagulant used for the treatment of thrombophlebitis, embolism, and thrombosis.
  • I will be reviewing the existing scientific literature and searching out which GAG molecules could be pharmacologically active.
  • For more information about Lui Franciosi and his company Franciosi Consulting Ltd., please visit https://franciosiconsulting.com/ or his YouTube Channel https://www.youtube.com/channel/UC7PSoeH8yN-HuLg5xFi5Qxw/ .
  • Lui Franciosi founded Franciosi Consulting Ltd. in 2015 and is the president and CEO.